# Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients

> **NCT04176328** · PHASE1 · COMPLETED · sponsor: **Neupharma Srl** · enrollment: 12 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.

## Key facts

- **NCT ID:** NCT04176328
- **Lead sponsor:** Neupharma Srl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-25
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-09-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04176328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04176328, "Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04176328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*